[go: up one dir, main page]

US20090286838A1 - Treatment for cancer - Google Patents

Treatment for cancer Download PDF

Info

Publication number
US20090286838A1
US20090286838A1 US11/720,884 US72088405A US2009286838A1 US 20090286838 A1 US20090286838 A1 US 20090286838A1 US 72088405 A US72088405 A US 72088405A US 2009286838 A1 US2009286838 A1 US 2009286838A1
Authority
US
United States
Prior art keywords
unsubstituted
substituted
alkenylalkyl
cycloalkylalkyl
arylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/720,884
Other languages
English (en)
Inventor
David L. Morris
Mohammad Hossein Pourgholami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewSouth Innovations Pty Ltd
Original Assignee
NewSouth Innovations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2004906983A external-priority patent/AU2004906983A0/en
Application filed by NewSouth Innovations Pty Ltd filed Critical NewSouth Innovations Pty Ltd
Assigned to NEWSOUTH INNOVATIONS PTY LIMITED reassignment NEWSOUTH INNOVATIONS PTY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MORRIS, DAVID L., POURGHOLAMI, MOHAMMAD HOSSEIN
Publication of US20090286838A1 publication Critical patent/US20090286838A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to methods and compositions for the treatment of tumours.
  • Paclitaxel has activity against a broad band of tumour types, including breast, ovarian, lung, head and neck cancers. Paclitaxel also has activity in other malignancies that are refractory to conventional chemotherapy, including previously-treated lymphoma and small cell lung cancers and oesophageal, gastric, endometrial, bladder and germ cell tumours (Mekhail and Markman, 2002; Yamazaki et al., 1998). It is one of the most unique, and successful, chemotherapeutic agents currently used in the clinic for cancer treatment. However major problems associated with paclitaxel therapy exist. One of these is toxicity.
  • Benzimidazole carbamates that have an opposing mode of action to the taxoids in that they inhibit microtubule polymerization rather than polymerize tubulin.
  • Benzimidazole carbamates include albendazole, a broad spectrum anthelmintic used clinically for the treatment of a number of parasitic infections (Horton, 2000).
  • albendazole has an anti-proliferative effect on a range of cancer cell lines in vitro and on cancers in animal models and clinical studies (WO 02/076454, the disclosure of which is incorporated herein by reference).
  • albendazole potentiates the effect of paclitaxel in human cancer cells, both in paclitaxel-sensitive and paclitaxel-resistant cell lines, such that used in combination these drugs have an additive or synergistic effect in inhibiting cancer cell proliferation.
  • a method for the treatment of a tumour in a subject comprising administering to the subject an effective amount of at least one taxoid and an effective amount of at least one benzimidazole carbamate compound of formula I:
  • the benzimidazole carbamate compound may be a compound of Formula II:
  • the benzimidazole carbamate compound may be selected from the group consisting of albendazole, albendazole sulphoxide, mebendazole, flubendazole, triclabendazole, oxfenbendazole, luxabendazole, cambendazole, oxibendazole, parbendazole, thiabendazole, cyclobendazole, dribendazole, etibendazole and fenbendazole.
  • the benzimidazole carbamate compound is albendazole, or a metabolite, derivative or analogue thereof.
  • the taxoid may be paclitaxel, docataxel, or a metabolite, derivative or analogue thereof.
  • the tumour may be a liver, ovarian, colorectal, lung, small cell lung, breast, prostate, pancreatic, renal, gastric, endometrial, oesophageal, head or neck tumour, peritoneal carcinomatosis, leukaemia, lymphoma, sarcoma or secondary metastases thereof.
  • the tumour may be insensitive to treatment with one or more antimitotic drugs.
  • the one or more antimitotic drugs may be selected from a taxoid, a Vinca alkaloid and a colchicinoid.
  • the tumour is a taxoid-insensitive tumour.
  • the amount of taxoid administered may be an amount otherwise ineffective to treat the tumour if administered alone.
  • the taxoid and the benzimidazole carbamate compound may be administered simultaneously or sequentially. Accordingly, the taxoid and the benzimidazole carbamate compound may be present in a single pharmaceutical composition or in separate compositions. The taxoid and the benzimidazole carbamate compound may be administered systemically.
  • a method for the treatment of a tumour in a subject comprising administering to the subject an effective amount of paclitaxel and an effective amount of albendazole.
  • the paclitaxel and albendazole may be administered simultaneously or sequentially. Accordingly, the paclitaxel and albendazole may be present in a single pharmaceutical composition or in separate compositions.
  • the taxoid and the benzimidazole carbamate compound may be administered systemically.
  • a pharmaceutical composition comprising at least one taxoid and at least one benzimidazole carbamate compound of formula I:
  • the benzimidazole carbamate compound may be a compound of Formula II:
  • the benzimidazole carbamate compound may be a compound of Formula III:
  • the benzimidazole carbamate compound may be selected from the group consisting of albendazole, albendazole sulphoxide, mebendazole, flubendazole, triclabendazole, oxfenbendazole, luxabendazole, cambendazole, oxibendazole, parbendazole, thiabendazole, cyclobendazole, dribendazole, etibendazole and fenbendazole.
  • the benzimidazole carbamate compound is albendazole, or a metabolite, derivative or analogue thereof.
  • the taxoid may be paclitaxel, docataxel, or a metabolite, derivative or analogue thereof.
  • composition may further comprise one or more pharmaceutically acceptable carriers, adjuvants or diluents.
  • composition may include one or more pharmaceutically acceptable carriers, adjuvants or diluents.
  • compositions for the treatment of a tumour in a subject comprising at least one taxoid and at least one benzimidazole carbamate compound of formula I.
  • the tumour may be a liver, ovarian, colorectal, lung, small cell lung, breast, prostate, pancreatic, renal, gastric, endometrial, oesophageal, head or neck tumour, peritoneal carcinomatosis, leukaemia, lymphoma, sarcoma or secondary metastases thereof.
  • the tumour may be insensitive to treatment with one or more antimitotic drugs.
  • the one or more antimitotic drugs may be selected from a taxoid, a Vinca alkaloid and a colchicinoid.
  • the tumour is a taxoid-insensitive tumour.
  • compositions for the treatment of a taxoid-insensitive tumour in a subject comprising paclitaxel and albendazole.
  • an eighth aspect of the present invention there is provided a method for the treatment of a tumour in a subject, the method comprising administering to the subject an effective amount of a composition according to the third, fourth or fifth aspect.
  • a ninth aspect of the present invention there is provided a use of at least one taxoid and at least one benzimidazole carbamate compound of formula I for the manufacture of a medicament for the treatment of a tumour in a subject.
  • a method for the treatment of a tumour in a subject comprising administering to the subject an effective amount of at least one benzimidazole carbamate compound of formula I:
  • the tumour may be insensitive to one or more of a taxoid, a Vinca alkaloid and a colchicinoid.
  • the taxoid may be paclitaxel.
  • the Vinca alkaloid may be vincristine.
  • the colchicinoid may be colchicine.
  • the tumour is insensitive to at least paclitaxel.
  • an eleventh aspect of the present invention there is provided the use of at least one benzimidazole carbamate compound of formula I for the manufacture of a medicament for the treatment of a tumour insensitive to at least one anti-mitotic drug.
  • the subject is typically human.
  • isomers including stereoisomers and geometric Isomers of the compounds of Formula I, II and III, as well as tautomeric forms thereof.
  • treating and “treatment” refer to any and all uses which remedy a condition or symptoms, prevent the establishment of a condition or disease, or otherwise prevent, hinder, retard, or reverse the progression of a condition or disease or other undesirable symptoms in any way whatsoever.
  • the term “effective amount” includes within its meaning a non-toxic but sufficient amount of an agent or compound to provide the desired effect. The exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered and the mode of administration and so forth. Thus, it is not possible to specify an exact “effective amount”. However, for any given case, an appropriate “effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.
  • the term “insensitive” refers to a tumour or portion thereof which is refractory, to some degree, to treatment with a particular therapeutic agent.
  • the term “insensitive” therefore is used to describe tumours otherwise referred to as resistant, for example paclitaxel-resistant.
  • this term is not limited to tumours which show complete or even significant levels of resistance to the therapeutic agent in question, but rather includes within its scope tumours that retain sensitivity to the agent but which display a diminished responsiveness to the agent when compared to sensitive tumours.
  • alkyl as used herein, includes within its meaning monovalent, saturated, straight and branched chain hydrocarbon radicals.
  • alkenyl as used herein, includes within its meaning, monovalent, straight and branched chain hydrocarbon radicals having at least one double bond.
  • aryl as used herein, includes within its meaning monovalent, single, polynuclear, conjugated and fused aromatic hydrocarbon radicals.
  • FIG. 1 Cytotoxic activity of albendazole and paclitaxel in inhibiting proliferation of OVCAR-3 cells in vitro.
  • A Dose-response inhibition of cell proliferation by albendazole alone.
  • B Dose-related inhibition of proliferation by paclitaxel and potentiation of this effect when cells were co-incubated with 0.25 ⁇ M albendazole. Cell proliferation was measured using a sulforhodamine B assay. Results are presented as the % of control (vehicle treated cells).
  • FIG. 2 Cytotoxic activity of albendazole and paclitaxel in inhibiting proliferation of SKOV-3 cells in vitro.
  • A Dose-response inhibition of cell proliferation by albendazole alone.
  • B Dose-related inhibition of proliferation by paclitaxel and potentiation of this effect when cells were co-incubated with 0.25 ⁇ M albendazole. Cell proliferation was measured using a sulforhodamine B assay. Results are presented as the % of control (vehicle treated cells).
  • FIG. 3 Cytotoxic activity of albendazole and paclitaxel in inhibiting proliferation of 1A9 cells in vitro.
  • A Dose-response inhibition of cell proliferation by albendazole alone.
  • B Dose-related inhibition of proliferation by paclitaxel alone.
  • C Combined effect of co-incubation of 1A9 cells with varying doses of paclitaxel and 0.1 ⁇ M albendazole. Cell proliferation was measured using a sulforhodamine B assay. Results are presented as the % of control (vehicle treated cells).
  • FIG. 4 Cytotoxic activity of albendazole and paclitaxel in inhibiting proliferation of 1A9PTX22 cells in vitro.
  • A Dose-response inhibition of cell proliferation by albendazole alone.
  • B Dose-related inhibition of proliferation by paclitaxel alone.
  • C Combined effect of co-incubation of 1A9 cells with varying doses of paclitaxel and 0.1 ⁇ M albendazole. Cell proliferation was measured using a sulforhodamine B assay. Results are presented as the % of control (vehicle treated cells).
  • FIG. 5 Cytotoxic activity of vincristine (A) and colchicine (B) in inhibiting proliferation of 1A9 and 1A9PTX22 cells in vitro.
  • Concentrations of vincristine (A) shown are 0.1 nM, 0.5 nM, 1 nM, 5 nM, 10 nM, 50 nM and 100 nM.
  • Concentrations of colchicine (B) shown are 0.1 nM, 0.5 nM, 1 nM, 5 nM, 10 nM, 50 nM, 100 nM, 500 nM and 1000 nM.
  • Cell proliferation was measured using a sulforhodamine B assay—the percentage of cells alive (cell growth) was calculated by defining the optical density of untreated cells (control) as 100%. Values represent the mean ⁇ SD of 8 replicate experiments, each repeated at least twice.
  • Dose-related toxicity and resistance are significant factors limiting the adoption and efficacy of treatment of patients with cancer using antmitotic drugs such as paclitaxel.
  • the strategy of increasing the dose of paclitaxel to overcome resistance merely exacerbates the problems of paclitaxel toxicity and the occurrence of side effects, while also potentially promoting the development of increased drug resistance.
  • albendazole potentiates the effect of paclitaxel in inhibiting proliferation of human cancer cells.
  • the effect is observed both in paclitaxel-sensitive and paclitaxel-resistant human cancer cells.
  • the inventors have also demonstrated that the paclitaxel-resistant tumour cells are hypersensitive to albendazole, a member of a different class of anti-tubulin agents. This is a particularly surprising finding as one skilled in the art would expect that a cell resistant to one type of anti-tubulin agent would be equally resistant to another. The inventors have demonstrated that this is not necessarily the case.
  • the addition of albendazole to paclitaxel may lead to a reduction of the paclitaxel dose required to produce an antitumour effect.
  • the use of albendazole either in the presence or absence of a paclitaxel treatment regimen may lead to tumour responsiveness and thus a beneficial therapeutic effect previously unattainable.
  • typically in paclitaxel-resistant cell lines an approximately 50-fold increase in paclitaxel concentration is required to achieve a similar response to that observed in paclitaxel-sensitive cells.
  • one aspect of the present invention provides a method for the treatment of a tumour in a subject, the method comprising administering to the subject an effective amount of at least one taxoid and an effective amount of at least one benzimidazole carbamate compound of formula I:
  • benzimidazole carbamate compound is a compound of formula II
  • cancer cells highly resistant to paclitaxel and partially resistant to vincristine and colchicine are hypersensitive to the anti-proliferative effects of albendazole.
  • benzimidazole carbamates such as albendazole.
  • At present resistance is combated by increasing the dosage of the agent to which resistance has developed, thereby increasing the risk of side effects such as toxicity and leading to the development of greater resistance and failure of the therapy.
  • the clinical application of benzimidazole carbamates in the treatment of tumours resistant to drugs such as paclitaxel overcomes these inherent deficiencies in the prior art approach.
  • an aspect of the present invention provides a method for the treatment of a tumour in a subject, wherein the tumour is insensitive to one or more anti-mitotic drugs, the method comprising administering to the subject an effective amount of at least one benzimidazole carbamate compound of formula I, II, or III as defined above.
  • the tumour may show complete or partial resistance to one or more of the following: taxanes, Vinca alkaloids and colchicinoids, or derivatives or analogues thereof.
  • Albendazole or a metabolite, derivative or analogue thereof is one benzimidazole carbamate particularly useful in the methods and compositions of the present invention.
  • albendazole carbamate particularly useful in the methods and compositions of the present invention.
  • other benzimidazole carbamates may also be employed.
  • benzimidazole carbamates include, but are not limited to, mebendazole, flubendazole, triclabendazole, oxfenbendazole, luxabendazole, cambendazole, oxibendazole, parbendazole, thiabendazole, cyclobendazole, dribendazole, etibendazole and fenbendazole.
  • the taxoid is paclitaxel or a metabolite, derivative or analogue thereof, or doclitaxel or a metabolite, derivative or analogue thereof.
  • taxoids may also be employed.
  • a large number of derivatives of paclitaxel and docataxel are currently in the experimental phase or in clinical trial. It will be understood by those skilled in the art that such derivatives are within the scope of the methods and compositions of the invention.
  • each component of the combination may be administered at the same time, or sequentially in any order, or at different times, so as to provide the desired therapeutic effect.
  • the components may be administered by the same route of administration, although it is not necessary for this to be so.
  • the components may be formulated together in a single dosage unit as a combination product.
  • the methods of the present invention may further comprise the administration of one or more corticosteroids and/or antihistamines (such as diphenydramine), for example as a pre-treatment, to counteract the risk of the patient having an adverse reaction to the taxoid.
  • the methods of the invention may comprise the administration of one or more potentiators of the effect of the taxoid and/or benzimidazole carbamate compound on the tumour to be treated.
  • Such administration may be concomitant with the administration of either or both of the taxoid and the benzimidazole carbamate compound.
  • a suitable potentiator of benzimidazole carbamates is an isoquinoline such as praziquantel.
  • tumours which may be treated using methods and compositions of the present invention include liver, ovarian, colorectal, lung, small cell lung, breast, prostate, pancreatic, renal, gastric, endometrial, oesophageal, head or neck tumours, peritoneal carcinomatosis, leukaemia, lymphomas, sarcomas or secondary metastases thereof.
  • compounds and compositions may be administered by any suitable route, either systemically, regionally or locally.
  • the particular route of administration to be used in any given circumstance will depend on a number of factors, including the nature of the tumour to be treated, the severity and extent of the tumour, the required dosage of the particular compounds to be delivered and the potential side-effects of the compounds.
  • administration may be regional rather than systemic.
  • Regional administration provides the capability of delivering very high local concentrations of the desired compounds to the required site and thus is suitable for achieving the desired therapeutic or preventative effect whilst avoiding exposure of other organs of the body to the compounds and thereby potentially reducing side effects.
  • administration according to embodiments of the invention may be achieved by any standard routes, including intracavitary, intravesical, intramuscular, intraarterial, intravenous, subcutaneous, topical or oral.
  • Intracavitary administration may be intraperitoneal or intrapleural,
  • administration may be via intravenous infusion or intraperitoneal administration.
  • suitable compositions may be prepared according to methods which are known to those of ordinary skill in the art and may include pharmaceutically acceptable diluents, adjuvants and/or excipients.
  • the diluents, adjuvants and excipients must be “acceptable” in terms of being compatible with the other ingredients of the composition, and not deleterious to the recipient thereof.
  • Examples of pharmaceutically acceptable diluents are demineralised or distilled water, saline solution; vegetable based oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oils such as peanut oil, safflower oil, olive oil, cottonseed oil, maize oil, sesame oil, arachis oil or coconut oil; silicone oils, including polysiloxanes, such as methyl polysiloxane, phenyl polysiloxane and methylphenyl polysolpoxane; volatile silicones; mineral oils such as liquid paraffin, soft paraffin or squalane; cellulose derivatives such as methyl cellulose, ethyl cellulose, carboxymethylcellulose, sodium carboxymethylcellulose or hydroxypropylmethylcellulose; lower alkanols, for example ethanol or iso-propanol; lower aralkanols; lower polyalkylene glycols or lower alkylene glycols, for example polyethylene glycol,
  • non-toxic parenterally acceptable diluents or carriers can include, Ringer's solution, medium chain triglyceride (MCT), isotonic saline, phosphate buffered saline, ethanol and 1,2 propylene glycol.
  • MCT medium chain triglyceride
  • isotonic saline phosphate buffered saline
  • ethanol 1,2 propylene glycol.
  • paclitaxel a commonly used carrier or vehicle for paclitaxel is Cremaphor EL.
  • Paclitaxel is typically prepared in 50% Cremaphor EL and 50% ethanol.
  • suitable carriers, diluents, excipients and adjuvants for oral use include peanut oil, liquid paraffin, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, gum acacia, gum tragacanth, dextrose, sucrose, sorbitol, mannitol, gelatine and lecithin.
  • these oral formulations may contain suitable flavouring and colourings agents.
  • the capsules When used in capsule form the capsules may be coated with compounds such as glyceryl monostearate or glyceryl distearate which delay disintegration.
  • Adjuvants typically include emollients, emulsifiers, thickening agents, preservatives, bactericides and buffering agents.
  • Solid forms for oral administration may contain binders acceptable in human and veterinary pharmaceutical practice, sweeteners, disintegrating agents, diluents, flavourings, coating agents, preservatives, lubricants and/or time delay agents.
  • Suitable binders include gum acacia, gelatine, corn starch, gum tragacanth, sodium alginate, carboxymethylcellulose, hydroxypropylmethylcellulose or polyethylene glycol.
  • Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine.
  • Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, guar gum, xanthan gum, bentonite, alginic acid or agar.
  • Suitable diluents include lactose, sorbitol, mannitol, dextrose, kaolin, cellulose, calcium carbonate, calcium silicate or dicalcium phosphate.
  • Suitable flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring.
  • Suitable coating agents include polymers or copolymers of acrylic acid and/or methacrylic acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten.
  • Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite.
  • Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc.
  • Suitable time delay agents include glyceryl monostearate or glyceryl distearate.
  • Liquid forms for oral administration may contain, in addition to the above agents, a liquid carrier.
  • suitable liquid carriers include water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, arachis oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohols, triglycerides or mixtures thereof.
  • Suspensions for oral administration may further comprise dispersing agents and/or suspending agents.
  • Suitable suspending agents include sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, poly-vinyl-pyrrolidone, sodium alginate or acetyl alcohol.
  • Suitable dispersing agents include lecithin, polyoxyethylene esters of fatty acids such as stearic acid, polyoxyethylene sorbitol mono- or di-oleate, -stearate or -laurate, polyoxyethylene sorbitan mono- or di-oleate, -stearate or -laurate and the like.
  • Emulsions for oral administration may further comprise one or more emulsifying agents.
  • Suitable emulsifying agents include dispersing agents as exemplified above or natural gums such as guar gum, gum acacia or gum tragacanth.
  • parenterally administrable compositions are apparent to those skilled in the art, and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa., hereby incorporated by reference herein.
  • the composition may Incorporate any suitable surfactant such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof.
  • suitable surfactant such as an anionic, cationic or non-ionic surfactant such as sorbitan esters or polyoxyethylene derivatives thereof.
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
  • compositions may also be administered in the form of liposomes.
  • Liposomes are generally derived from phospholipids or other lipid substances, and are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming liposomes can be used.
  • the compositions in liposome form may contain stabilisers, preservatives, excipients and the like.
  • the preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.
  • the effective dose level of the administered compound for any particular subject will depend upon a variety of factors including: the type of tumour being treated and the stage of the tumour; the activity of the compound employed; the composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of sequestration of compounds; the duration of the treatment; drugs used in combination or coincidental with the treatment, together with other related factors well known in medicine.
  • the taxoid may be present in the composition in a concentration of at least about 1 pM.
  • concentration of the taxoid in the composition may be from about 1 pM to about 50 nM, from about 0.01 nM to about 10 nM, from about 0.05 nM to about 5 nM, or from about 0.1 nM to about 1 nM.
  • the benzimidazole carbamate compound may be present in the composition in a concentration of at least about 0.005 ⁇ M.
  • concentration of the benzimidazole carbamate in the composition may be from about 0.005 ⁇ M to about 10 ⁇ M, from about 0.01 ⁇ M to about 1 ⁇ M, from about 0.1 ⁇ M to about 0.5 ⁇ M, or from about 0.1 ⁇ M to about 0.25 ⁇ M.
  • an effective dosage of a composition for administration to a patient is expected to be in the range of about 0.01 mg to about 150 mg per kg body weight per 24 hours; typically, about 0.1 mg to about 150 mg per kg body weight per 24 hours; about 0.1 mg to about 100 mg per kg body weight per 24 hours; about 0.5 mg to about 100 mg per kg body weight per 24 hours; or about 1.0 mg to about 100 mg per kg body weight per 24 hours. More typically, an effective dose range is expected to be in the range of about 5 mg to about 50 mg per kg body weight per 24 hours.
  • an effective dosage may be up to about 5000 mg/m 2 .
  • an effective dosage is expected to be in the range of about 10 to about 5000 mg/m 2 , typically about 10 to about 2500 mg/m 2 , about 25 to about 2000 mg/m 2 , about 50 to about 1500 mg/m 2 , about 50 to about 1000 mg/m 2 , or about 75 to about 600 mg/m 2 .
  • OVCAR-3, SKOV-3, 1A9 and 1A9PTX22 were used.
  • OVCAR-3 and SKOV-3 cells were obtained from the American Type Culture Collection (ATCC) and maintained on RPMI medium and McCoy5A medium respectively according to ATCC instructions.
  • 1A9 is a clone of the human ovarian carcinoma cell line, A2780 (Sackett et al., 1997).
  • 1A9PTX22 is a paclitaxel resistant subclone of 1A9 cells, isolated as an individual clone in a single step selection by exposing 1A9 cells to 5 ng/ml paclitaxel in the presence of 5 ⁇ g/ml verapamil, a Pgp antagonist (Giannakakou et al., 1997). Cells were maintained in 15 ng/ml paclitaxel and 5 ⁇ g/ml verapamil continuously.
  • SRB Sulforhodamine B
  • Cells were harvested from exponential phase cultures by trypsinizabon, counted and plated in 96-well plates. Optimal seeding densities for each cell line were determined to ensure exponential growth during a 5-day assay. Seeding densities were 5000, 1000, 400 and 3500 cells per well for OVCAR-3, SKOV-3, 1A9 and 1A9PTX22 cells, respectively. Cells plated in 96-well tissue culture plates were treated with 100 ⁇ l cell culture medium containing various concentrations of albendazole, paclitaxel or a combination of the two. Both albendazole and paclitaxel were originally made up in absolute ethanol and subsequently diluted with cell culture medium to give the desired drug concentrations with a final ethanol concentration of 1%.
  • Treatment media were replaced on alternate days. At the end of the treatment period (5 days), wells were assayed for cellular protein content.
  • the SRB assay was performed according to the method described by Skehan et at. (1990) and Papazisis et al. (1997), with minor modifications.
  • the culture medium was aspirated prior to fixation of the cells by the addition of 100 ⁇ l 10% cold trichloroacetic acid. After an hour incubation at 4° C., cells were washed five times with water. The cells were then stained with 200 ⁇ l 0.4% SRB dissolved in 1% acetic acid for at least 15 min and subsequently washed four times with 1% acetic acid to remove unbound stain.
  • the plates were left to dry at room temperature and bound protein stain was solubilized with 100 ⁇ l 10 mM un-buffered Tris base [tris(hydroxymethyl)aminomethane)] before reading the optical density (OD) at 570 nm.
  • sensitivity of each line was initially tested by incubating cells with various concentrations of albendazole or paclitaxel for 5 days.
  • the SRB assay was performed at the end of the treatment period to determine cell response to drug treatment.
  • FIG. 1 Data from OVCAR-3 cells are presented in FIG. 1 , where response to various doses of albendazole is depicted in FIG. 1A and response to various doses of paclitaxel alone or in combination with albendazole (0.25 ⁇ M) is presented in FIG. 1B .
  • FIG. 1B the addition of 0.25 ⁇ M albendazole to the paclitaxel containing incubation medium led to a complete halt of cell proliferation.
  • SKOV-3 cells responded to albendazole, paclitaxel or the combination in a similar fashion.
  • a dose-response inhibition of cell proliferation by paclitaxel was profoundly potentiated upon co-incubation with albendazole.
  • Treatment of these cells with 0.01 nM paclitaxel alone led to 14.5% inhibition of cell proliferation and with 0.25 ⁇ M albendazole alone to a 48.4% reduction.
  • paclitaxel (0.01 nM) and albendazole (0.25 ⁇ M) there was 69.4% reduction in cell proliferation (p ⁇ 0.001 compared to paclitaxel alone).
  • FIG. 3 This inhibitory effect was more intense in 1A9 cells ( FIG. 3 ), where treatment with a low albendazole concentration of 0.1 ⁇ M alone ( FIG. 3A ) or treatment with 0.1 nM paclitaxel alone ( FIG. 3B ) led to 11.8% and 21.8% inhibition respectively. Co-incubation of the cells with the two drugs at these concentrations led to 87.7% inhibition of proliferation (p ⁇ 0.001) ( FIG. 3C ).
  • Taxoids such as paclitaxel
  • tubulin-binding drugs are the Vinca alkaloids, exemplified by vincristine, vinblastine and vinorelbine.
  • Vinca alkaloids interfere with a cells ability to properly form the mitotic spindle by preventing the normal polymerization of microtubules. They have importance in the treatment of leukemia, lymphomas, small cell lung cancer, and other malignancies.
  • a third class of anti-tubulin drugs exemplified by colchicine, is comprised of a structurally diverse collection of small molecules that are related by the fact that all bind to a common site on tubulin known as the colchicine site and prevent the normal polymerization of microtubules.
  • the present inventors have shown that the paclitaxel resistant cell line 1A9PTX22 displays increased sensitivity to the antiproliferative effects of albendazole compared to the paclitaxel sensitive parent line 1A9.
  • the inventors investigated the level of sensitivity of these cells to representatives of two other classes of antimitotic drugs, namely vincristine and colchicine.
  • 1A9 and 1A9PTX22 cells plated in 96-well tissue culture plates were treated with 100 ⁇ l cell culture medium containing various concentrations of vincristine and colchicine for 72 hours and SRB assays conducted as described above.
  • paclitaxel see Example 1
  • both vincristine and colchicine were originally made up in absolute ethanol and subsequently diluted with cell culture medium to give the desired drug concentrations with a final ethanol concentration of 1%.
  • the degree of sensitivity of 1A9PTX22 cells to both vincristine and colchicine is significantly reduced when compared to that of the parent cell line 1A9.
  • the partial resistance of 1A9PTX22 is apparent for vincristine at concentrations of 5 nM and above and for colchicine at 100 nM and above (p ⁇ 0.001).
  • compositions are outlined below. The following are to be construed as merely illustrative examples of compositions and not as a limitation of the scope of the present invention in any way.
  • composition for Parenteral Administration Composition for Parenteral Administration
  • a composition for parenteral injection could be prepared to contain 0.05 mg to 5 g of albendazole and 0.05 mg to 5 g of paclitaxel in 10 mls to 2 litres of 0.1-10% carboxymethylcellulose.
  • composition for intravenous infusion may comprise 250 ml of sterile Ringer's solution, and 0.05 mg to 5 g of albendazole and 0.05 mg to 5 g of paclitaxel.
  • a composition of a suitable agent in the form of a capsule may be prepared by filling a standard two-piece hard gelatin capsule with 500 mg of albendazole, in powdered form, 500 mg of paclitaxel, 100 mg of lactose, 35 mg of talc and 10 mg of magnesium stearate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/720,884 2004-12-06 2005-12-06 Treatment for cancer Abandoned US20090286838A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2004906983A AU2004906983A0 (en) 2004-12-06 Treatment for cancer
AU2004906983 2004-12-06
PCT/AU2005/001839 WO2006060853A1 (en) 2004-12-06 2005-12-06 Treatment for cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2005/001839 A-371-Of-International WO2006060853A1 (en) 2004-12-06 2005-12-06 Treatment for cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/457,860 Division US8835478B2 (en) 2004-12-06 2012-04-27 Treatment for cancer

Publications (1)

Publication Number Publication Date
US20090286838A1 true US20090286838A1 (en) 2009-11-19

Family

ID=36577596

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/720,884 Abandoned US20090286838A1 (en) 2004-12-06 2005-12-06 Treatment for cancer
US13/457,860 Expired - Fee Related US8835478B2 (en) 2004-12-06 2012-04-27 Treatment for cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/457,860 Expired - Fee Related US8835478B2 (en) 2004-12-06 2012-04-27 Treatment for cancer

Country Status (9)

Country Link
US (2) US20090286838A1 (es)
EP (1) EP1830847B1 (es)
JP (1) JP2008522984A (es)
KR (1) KR101287917B1 (es)
CN (1) CN101111248A (es)
CA (1) CA2589828C (es)
ES (1) ES2528363T3 (es)
PT (1) PT1830847E (es)
WO (1) WO2006060853A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210015757A1 (en) * 2019-07-18 2021-01-21 Nano Targeting & Therapy Biopharma Inc Drug delivery by pore-modified mesoporous silica nanoparticles

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043093A1 (en) * 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
KR20090046142A (ko) 2007-11-05 2009-05-11 삼성전자주식회사 입력 필체 자동 변환 시스템 및 방법
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
WO2010135534A2 (en) * 2009-05-20 2010-11-25 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
US20120202840A1 (en) * 2009-10-09 2012-08-09 University Health Network Use of Flubendazole and Vinca Alkaloids for Treatment of Hematological Diseases
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
NZ729555A (en) 2012-08-06 2017-08-25 Pitney Pharmaceuticals Pty Ltd Compounds for the treatment of mtor pathway related diseases
CN103054858A (zh) * 2013-01-21 2013-04-24 杭州雷索药业有限公司 奥苯达唑在制备抗血管生成类药物中的应用
AU2014344789B2 (en) * 2013-11-01 2019-10-03 Pitney Pharmaceuticals Pty Limited Pharmaceutical combinations for the treatment of cancer
CN111388469B (zh) * 2019-10-21 2021-11-02 温州医科大学 一种芬苯达唑在制备抗肿瘤药物中的应用
JP7568309B2 (ja) * 2019-10-21 2024-10-16 アキュラ ナノメディスン コーポレーション 癌を処置する方法
KR102516896B1 (ko) * 2020-10-19 2023-04-03 고려대학교 산학협력단 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
CN113648308A (zh) * 2021-09-14 2021-11-16 东莞市人民医院 奥芬达唑作为抗卵巢癌药物的应用
FR3151700A1 (fr) 2023-07-28 2025-01-31 Soitec Procédé de fabrication d’un substrat de diamant ou d’un matériau III-V pour applications en microélectronique
CN118908896A (zh) * 2024-09-02 2024-11-08 广东海洋大学 4-（1H-苯并[d]咪唑-2-基）-N，N-双（2-氯乙基）苯胺衍生物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041669A2 (en) * 1999-01-15 2000-07-20 Angiogene Pharmaceuticals Ltd. Benzimidazole vascular damaging agents
WO2001012169A2 (en) * 1999-08-13 2001-02-22 The Procter & Gamble Company Method of cancer treatment
WO2002076454A1 (en) * 2001-03-26 2002-10-03 Unisearch Limited Method for treatment of cancer and compositions for use therein

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) * 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
WO2001083457A2 (en) * 2000-04-28 2001-11-08 The Procter & Gamble Company Benzimidazole-2-carbamates and their use in cancer treatment
WO2002067932A1 (en) * 2001-01-11 2002-09-06 Board Of Regents, The University Of Texas System Antihelminthic drugs as a treatment for hyperproliferative diseases
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
ES2295695T3 (es) * 2002-08-02 2008-04-16 Nereus Pharmaceuticals, Inc. Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000041669A2 (en) * 1999-01-15 2000-07-20 Angiogene Pharmaceuticals Ltd. Benzimidazole vascular damaging agents
WO2001012169A2 (en) * 1999-08-13 2001-02-22 The Procter & Gamble Company Method of cancer treatment
WO2002076454A1 (en) * 2001-03-26 2002-10-03 Unisearch Limited Method for treatment of cancer and compositions for use therein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Tahir et al. Cancer Research, 2001, vol. 61, pages 5480-5485 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210015757A1 (en) * 2019-07-18 2021-01-21 Nano Targeting & Therapy Biopharma Inc Drug delivery by pore-modified mesoporous silica nanoparticles

Also Published As

Publication number Publication date
EP1830847A1 (en) 2007-09-12
PT1830847E (pt) 2015-02-05
CN101111248A (zh) 2008-01-23
JP2008522984A (ja) 2008-07-03
ES2528363T3 (es) 2015-02-09
KR20070112113A (ko) 2007-11-22
CA2589828A1 (en) 2006-06-15
US20120214856A1 (en) 2012-08-23
EP1830847B1 (en) 2014-11-19
KR101287917B1 (ko) 2013-07-23
EP1830847A4 (en) 2012-09-12
CA2589828C (en) 2014-07-08
US8835478B2 (en) 2014-09-16
WO2006060853A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
US8835478B2 (en) Treatment for cancer
JP2011173928A (ja) 癌処置のためのエポチロンの使用
US20050119352A1 (en) Method of treating cancers
WO1999043320A1 (en) Use of epothilones for the treatment of cancer
WO2009043093A1 (en) Hif inhibition
US7091193B2 (en) Therapeutic formulations
KR20040025895A (ko) 에포틸론 유도체를 사용하는 치료불응성 종양의 치료
KR20040028720A (ko) 치료불응성 종양 치료용 에포틸론 유도체
US20250073225A1 (en) Bifunctional compositions for the treatment of cancer
EP1784181B1 (en) Vegf inhibition
US20190076407A1 (en) Combination therapy for proliferative diseases
JP2011529950A (ja) 化学療法剤の経口製剤
AU2005313839B2 (en) Treatment for cancer
CA2849147A1 (en) Compositions comprising a taxoid and a benzimidazole carbamate for the treatment of cancer
AU2005279701B2 (en) VEGF inhibition
RU2242229C2 (ru) Применение эпотилонов для лечения рака
HK1103651B (en) Vegf inhibition
JP2007523190A (ja) 肺癌の治療のためのβ−ラパコンの使用
Pavlica et al. Systemic therapy of ovarian cancer–the mechanism of action of antineoplastic drugs
CA2530311A1 (en) Cancer treatment with epothilones
WO2008122798A2 (en) Pharmaceutical composition of an eg5 inhibitor and a microtubule interfering agent for the treatment of cancer

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEWSOUTH INNOVATIONS PTY LIMITED, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORRIS, DAVID L.;POURGHOLAMI, MOHAMMAD HOSSEIN;REEL/FRAME:022795/0925

Effective date: 20070821

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION